Details for New Drug Application (NDA): 206317

✉ Email this page to a colleague

NDA 206317 describes TRIFERIC, which is a drug marketed by Rockwell Medical Inc and is included in three NDAs. There are two patents protecting this drug. Additional details are available on the TRIFERIC profile page.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.

Summary for 206317

Tradename:	TRIFERIC
Applicant:	Rockwell Medical Inc
Ingredient:	ferric pyrophosphate citrate
Patents:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206317

Generic Entry Date for 206317^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up Dosage: SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS			Strength	27.2MG IRON/5ML (5.44MG IRON/ML)
Approval Date:	Jan 23, 2015	TE:		RLD:	Yes
Patent:	⤷ Sign Up	Patent Expiration:	Apr 17, 2029	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	SOLUTION;INTRAVENOUS			Strength	272MG IRON/50ML (5.44MG IRON/ML)
Approval Date:	Sep 4, 2015	TE:		RLD:	Yes

Expired US Patents for NDA 206317

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015	⤷ Sign Up	⤷ Sign Up
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for 206317

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 206317

Profile for product number 001

Profile for product number 002

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 206317